Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.120
+0.120 (3.00%)
At close: Jun 26, 2026, 4:00 PM EDT
4.200
+0.080 (1.94%)
After-hours: Jun 26, 2026, 7:31 PM EDT
Protara Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Protara Therapeutics stock have an average target of 26, with a low estimate of 24 and a high estimate of 28. The average target predicts an increase of 531.07% from the current stock price of 4.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 21, 2026.
Analyst Ratings
The average analyst rating for Protara Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $24 | Buy | Maintains | $24 | +482.52% | May 21, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $22 → $26 | Buy | Maintains | $22 → $26 | +531.07% | May 20, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $25 → $28 | Buy | Reiterates | $25 → $28 | +579.61% | May 20, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +555.34% | May 20, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.00M
EPS This Year
-1.39
from -1.34
EPS Next Year
-1.64
from -1.39
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 7.0M | |
| Avg | n/a | 1,000,000 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 12,570.0% |
| Avg | - | 8,126.5% |
| Low | - | 3,090.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.02 | -1.13 | |
| Avg | -1.39 | -1.64 | |
| Low | -2.10 | -2.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.